High effectiveness of efavirenz-based highly active antiretroviral therapy in HIV-1-infected patients with fewer than 100 CD4 cells/μl and opportunistic diseases: The Efa VIP study (Efavirenz in very immunosuppressed patients)

AIDS

Volumn 16, Issue 11, 2002, Pages 1554-1556

  Arribas, Jose R ^a   Pulido, Federico ^b   Miró, Jose M ^c   Costa, María A ^b   González, Juan ^a   Rubio, Rafael ^b   Peña, Jose M ^a   Torralba, Miguel ^b   Lonca, Montserrat ^c   Lorenzo, Alicia ^a   Del Palacio, Angel ^b   Vázquez, Juan José ^a   Gatell, Jose M ^c  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^c UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

DIDANOSINE; EFAVIRENZ; LAMIVUDINE; STAVUDINE; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; OXAZINE DERIVATIVE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AIDS RELATED COMPLEX; ARTICLE; DRUG EFFICACY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; MAJOR CLINICAL STUDY; MALE; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; T LYMPHOCYTE; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; DRUG EFFECT; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; LETTER; MIDDLE AGED; MORTALITY; RECURRENT DISEASE; RETROSPECTIVE STUDY; VIROLOGY;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; FEMALE; HIV-1; HUMAN; IMMUNOCOMPROMISED HOST; MALE; MIDDLE AGE; OXAZINES; RECURRENCE; RETROSPECTIVE STUDIES; HUMANS; MIDDLE AGED;

EID: 0037178333     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200207260-00014     Document Type: Article

References (11)

1. Low two-year risk of virologic failure with first regimen HAART
2. Recommendation of GESIDA (AIDS Study Group)/National Plan on AIDS with respect to the anti-retroviral treatment in adult patients infected with the human immunodeficiency virus in the year 2000 (I)
3. Prevention of opportunistic infections in adult and adolescent patients infected with the human immunodeficiency virus in the era of highly active antiretroviral therapy. Recommendations of the Grupo de Estudio del SIDA (GESIDA/Plan National sobre el SIDA)
4. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults
5. Successful virologic suppression with efavirenz in HIV-infected patients with low baseline CD4 cell counts: Post hoc results from Study 006
6. Response to first protease inhibitor- and efavirenz-containing antiretroviral combination therapy. The Swiss HIV Cohort Study
7. Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults
8. High incidence of herpes zoster in patients with AIDS soon after therapy with protease inhibitors
9. Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy
10. Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS
11. Inflammatory reactions in HIV-1-infected persons after initiation of highly active antiretroviral therapy